ReviewEndocrine pathology2017
Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review.
Review in Endocrine pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Aggressive follicular cell derived thyroid carcinoma: what do you need from the pathologist.Virchows Archiv : an international journal of pathology · 2026Review
- Impact of Subtype Variability on Clinical Features in Papillary Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2026Article
- RNA-binding protein RBM47 in health and disease: molecular mechanisms, preclinical evidence, and translational challenges.Frontiers in immunology · 2026Review
- Papillary thyroid carcinoma with metastasis to the femur as a rare cause of femoral fracture: A case report.Oncology letters · 2025Article
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Identification of prognostic and cellular senescence gene E2F1 of papillary thyroid carcinoma through bioinformatics analyses and experimental verification.Frontiers in genetics · 2025Article
- LINC00261 triggers DNA damage via the miR-23a-3p/CELF2 axis to mitigate the malignant characteristics ofBiochemistry and biophysics reports · 2024Article
- Cytologic hallmarks and differential diagnosis of papillary thyroid carcinoma subtypes.Journal of pathology and translational medicine · 2024Review
- Aggressive Types of Malignant Thyroid Neoplasms.Journal of clinical medicine · 2024Review
- Imprinted gene detection effectively improves the diagnostic accuracy for papillary thyroid carcinoma.BMC cancer · 2024Article
- Guiding the postoperative radioactive iodine-131 therapy for patients with papillary thyroid carcinoma according to the prognostic risk groups: a SEER-based study.Journal of cancer research and clinical oncology · 2023Article
- Circ_0011373 promotes papillary thyroid carcinoma progression by regulating miR-1271/LRP6 axis.Hormones (Athens, Greece) · 2023Article
- Metastatic recurrence of lung adenocarcinoma in thyroid clinically masquerading as primary thyroid cancer and immunohistochemically positive for thyroglobulin.BMJ case reports · 2023Article
- Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.The Journal of clinical endocrinology and metabolism · 2023Review
- Review
- Sonographic appearances of hobnail papillary thyroid carcinoma: A case report of a rare tumour.Ultrasound (Leeds, England) · 2022Article
- Genetic Alterations in Papillary Thyroid Carcinoma With HashimotoFrontiers in oncology · 2022Article
- Transcription Factor E2F1 Exacerbates Papillary Thyroid Carcinoma Cell Growth and InvasionAnalytical cellular pathology (Amsterdam) · 2022Article
- Thyroid collision tumor containing oncocytic carcinoma, classical and hobnail variants of papillary carcinoma and areas of poorly differentiated carcinoma.Archives of endocrinology and metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma is the most common thyroid malignancy and it is usually associated with a good prognosis. However, recurrence, metastases, and cancer death may occur in 10 to 15% of patients with more aggressive types of papillary thyroid carcinoma, such as tall cell, columnar cell, solid variant, or the more recently described hobnail variant of papillary thyroid carcinoma. Papillary thyroid carcinoma with a prominent hobnail pattern is a moderately differentiated papillary thyroid carcinoma variant with aggressive clinical behavior and significant mortality. The hobnail variant of papillary thyroid carcinoma shows prominent hobnail features, which have also been referred to as micropapillary. The typical hobnail/micropapillary morphological features show loss of cellular polarity/cohesiveness and support an epithelial-mesenchymal transition as a possible mechanism of metastasis. BRAF p.V600E is the most common mutation in papillary thyroid carcinoma, including the hobnail variant; recent and continuing studies are focused on defining other molecular anomalies that may be useful for prognostic stratification and may provide therapeutic targets.
Indexed as
Identifiers
29019044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.